ABQ BioPark Botanic Garden

Artilysin®: Fearless Into the Post-antibiotic Era

Retrieved on: 
Thursday, December 15, 2022

To counter this threat, Lysando AG has developed the so-called Artilysin technology: Novel antimicrobial proteins with a unique mode of action.

Key Points: 
  • To counter this threat, Lysando AG has developed the so-called Artilysin technology: Novel antimicrobial proteins with a unique mode of action.
  • View the full release here: https://www.businesswire.com/news/home/20221215005034/en/
    Lysando AG has developed the so-called Artilysin technology: Novel antimicrobial proteins with a unique mode of action.
  • The Artilysin technology allows the Lysando team to design fit-for-purpose molecules by flexibly combining modules with antibacterial activity.
  • Moreover, the technology for example in topical applications acts locally, does not breach the body's natural barriers or disrupt our skin's natural defense system.

Lysando AG and Amicogen Inc. Sign General Development Agreement

Retrieved on: 
Tuesday, October 18, 2022

Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea.

Key Points: 
  • Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea.
  • In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model.
  • This collaboration has since been further intensified, now culminating in aforementioned general development agreement.
  • "Amicogen is our first choice for process development and scale-up of any new Artilysin", says Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG.

University of Maryland, Baltimore and Wexford Meeting Critical Demand for Wet Lab Space in Baltimore Region

Retrieved on: 
Thursday, September 22, 2022

BALTIMORE, Sept. 22, 2022 /PRNewswire/ -- University of Maryland, Baltimore (UMB) and Wexford Science & Technology, LLC, announced today that 4MLK, the newest development project in the University of Maryland BioPark, is slated to move forward, with groundbreaking this fall (2022) and delivering in summer 2024. The 8-story, 250,000-square-foot building, Phase I of a two-phase project representing a $320 million total capital investment, will provide critical wet laboratory space in downtown Baltimore for researchers and companies, flexible lab and office/support space for start-ups, and Class A office space, along with areas for convening and a conference center.

Key Points: 
  • "The BioPark is a highly sought-after location for companies seeking commercial wet lab space as well as connection to UMB and the vast resources we offer.
  • We are proud that 4MLK will deliver a high volume of new lab space to Baltimore, helping fill the severe shortage in our region."
  • "4MLK is the result of our strong, long-term partnership with UMB and critical focus on providing much needed world-class research space to private industry.
  • The UM BioPark offers high-quality lab and office space solutions for companies of all sizes, especially high-growth companies seeking connection with its academic partner, University of Maryland, Baltimore.

Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG

Retrieved on: 
Tuesday, September 6, 2022

Lysando AG market leader in the field of antimicrobial proteins is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June.

Key Points: 
  • Lysando AG market leader in the field of antimicrobial proteins is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June.
  • Dr. Geldmacher will be responsible for shaping Lysando's strategy and identifying areas where Lysando's technology can add the most value.
  • View the full release here: https://www.businesswire.com/news/home/20220906005285/en/
    Prior to joining Lysando AG, Dr. Geldmacher has been part of the consulting firm McKinsey & Company for almost nine years.
  • Dr. Fabian Geldmacher assumed the position of Director Strategy & Business Development on June 1, 2022.

Wilhelm von Haller is Chief Financial Officer of Lysando AG

Retrieved on: 
Tuesday, August 2, 2022

Lysando AG market leader in the field of antimicrobial proteins is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March.

Key Points: 
  • Lysando AG market leader in the field of antimicrobial proteins is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March.
  • View the full release here: https://www.businesswire.com/news/home/20220802005152/en/
    "Wilhelm von Haller brings exactly the type of experience in global finance and business operations we need now.
  • "Recent developments have confirmed that we have taken the right choice with Wilhelm von Haller, as he has already been setting many important new impulses for Lysando."
  • Lysando has developed one of the most promising technologies in the field of combatting bacterial infections," says CFO Wilhelm von Haller.

Vita Therapeutics Relocates to University of Maryland BioPark

Retrieved on: 
Monday, May 2, 2022

BALTIMORE, May 2, 2022 /PRNewswire/ -- The University of Maryland (UM) BioPark announced today that Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop cellular therapies to treat muscular dystrophies and solid tumors, has established offices and laboratory space within approximately 10,000 square feet of leased space in the BioPark. Vita Therapeutics will leverage the new space to bring together its 25+-person team under one roof for the first time with the goal of progressing its co-lead programs, VTA-100 and VTA-300. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients.

Key Points: 
  • "We proudly welcome Vita Therapeutics as the newest tenant within the BioPark," said James Hughes, President of the UM BioPark and Senior Vice President and Chief Enterprise and Economic Development Officerat University of Maryland, Baltimore.
  • Vita Therapeutics has completed Series A financing of $32 million and is currently working with numerous partners, including PanCella, Wyss Institute, and Johns Hopkins University, to advance clinical programs.
  • Vita Therapeutics is a biotechnology company generating state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers.
  • The UM BioPark offers high-quality lab and office space solutions for companies of all sizes, especially high-growth companies seeking connection with its academic partner, University of Maryland, Baltimore.

Iconic Wildflowers in Peril: New Report Highlights Threats to Trillium in North America

Retrieved on: 
Thursday, April 14, 2022

The report, The Conservation Status of Trillium in North America, presents the analysis of 53 plant taxa using two different methodologies.

Key Points: 
  • The report, The Conservation Status of Trillium in North America, presents the analysis of 53 plant taxa using two different methodologies.
  • Authors found that habitat loss, overpopulation of white-tailed deer, and habitat disturbance caused by feral pigs are the primary threats to North American Trillium.
  • Several species of invasive plants that substantially alter native habitats were also identified as major threats to Trillium species.
  • Knapp continued, This report represents work of the most knowledgeable experts and is the most comprehensive and detailed assessment of North America Trillium ever compiled.

Bioparker Corporation delivers innovation, interoperability solutions, and secure remote physiological monitoring on a mission to revolutionize the healthcare industry.

Retrieved on: 
Tuesday, January 4, 2022

Bioparker provides customizable modules including a Remote Physiologic Monitoring (RPM) solution, allowing healthcare professionals to expand care services and improve patient outcomes for value-based care and fee-for-service healthcare models.

Key Points: 
  • Bioparker provides customizable modules including a Remote Physiologic Monitoring (RPM) solution, allowing healthcare professionals to expand care services and improve patient outcomes for value-based care and fee-for-service healthcare models.
  • Despite billions of dollars of investment in digital health, current solutions have failed to adapt and meet the needs of the modern healthcare system.
  • Recognizing the need to address these gaps, Bioparker founders have collaboratively developed a solution to revolutionize and deliver on the unfulfilled promises of digital health.
  • "Bioparker revolutionizes the delivery, management, accessibility, and cost of care through meaningful use and implementation of digital health technology.

Bioparker Corporation submits white paper to revolutionize The US Department of Veterans Affairs' Electronic Health Record system

Retrieved on: 
Thursday, December 16, 2021

WASHINGTON, Dec. 15, 2021 /PRNewswire/ -- Bioparker Corporation (Bioparker) submits white paper to revolutionize The US Department of Veterans Affairs' (VA) Electronic Health Record system.

Key Points: 
  • WASHINGTON, Dec. 15, 2021 /PRNewswire/ -- Bioparker Corporation (Bioparker) submits white paper to revolutionize The US Department of Veterans Affairs' (VA) Electronic Health Record system.
  • Bioparker provides the only Electronic Medical Record (EMR) and Electronic Health Record (EHR) system on the market that exceeds FHIR compliance regulations to offer instantaneous access to health data across the entire continuum of care.
  • According to a recent Health Affairs study, only 29.7 percent of hospitals engaged in all four domains of interoperability in 2015.
  • Americans, particularly American Veterans, deserve access to a secure, reliable, and trusted health care system.